Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Claudin-17 (CLDN17) is a tetraspan integral membrane protein belonging to the claudin family that forms part of tight junctions between epithelial or endothelial cells[1][3][6]. It acts as a channel-forming protein that is highly anion-selective, facilitating paracellular transport of chloride, hydrogencarbonate, and certain small organic anions, with predominant high expression in the kidney proximal tubule[3][4][6]. CLDN17 plays a critical role in establishing and regulating the paracellular barrier between cells, thus maintaining tissue-specific permeability and cell polarity[1][6][7]. Genetic studies suggest its locus is linked to diseases that involve disrupted barrier integrity, and its expression is modulated in response to tissue injury and in various pathological contexts, especially in the kidney and potentially in some tumors[1][3][4][5]. There are, as of 2024, no approved drugs directly targeting CLDN17, nor is it a recognized therapeutic target, although its importance in barrier function points to potential disease relevance if dysregulated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Claudin-17 (CLDN17).